Actelion is a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs as innovative treatments to serve high unmet medical needs. The company has its corporate headquarters in Allschwil/Basel, Switzerland where it was founded in 1997.
The company has proven its ability to discover new com¬pounds and to rapidly move them from research through development to commercialization. In particular, Actelion scientists were among the first to work in the field of en¬dothelin receptor antagonists, leading to its lead product, Tracleer®.
Actelion has over 30 operative affiliates around the world including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. These subsidiaries provide or will provide distribution, sales and marketing services.